Table 3 Adjusteda hazard ratios of death (and 95% confidence intervals) within 3 years of diagnosis
All patients | Surgical patientsb | |||
|---|---|---|---|---|
Factor | HR (95% CI) | P-value | HR (95% CI) | P-value |
Year of diagnosis | No statistically significant differences | |||
1993 | 1.00 | |||
1994 | 0.98 (0.87, 1.11) | 0.779 | ||
1995 | 0.94 (0.83, 1.06) | 0.309 | ||
1996 | 0.81 (0.72, 0.92) | 0.001 | ||
1997 | 0.88 (0.78, 1.00) | 0.043 | ||
Age groups | ||||
0–49 | 1.00 | 1.00 | ||
50–59 | 0.95 (0.75, 1.19) | 0.648 | 1.00 (0.69, 1.46) | 0.982 |
60–69 | 1.14 (0.92, 1.41) | 0.241 | 1.26 (0.88, 1.78) | 0.205 |
70–79 | 1.14 (0.92, 1.41) | 0.245 | 1.41 (0.99, 2.02) | 0.06 |
⩾80 | 1.41 (1.12, 1.76) | 0.003 | 1.83 (1.22, 2.75) | 0.003 |
Sex | No statistically significant differences | |||
Male | 1.00 | |||
Female | 0.92 (0.85, 1.00) | 0.042 | ||
Scottish co-morbidity index b | ||||
None | 1.00 | 1.00 | ||
1 condition | 1.24 (1.12, 1.37) | <0.001 | 1.09 (0.91, 1.32) | 0.351 |
⩾2 conditions | 1.25 (1.09, 1.42) | 0.001 | 1.51 (1.12, 2.05) | 0.007 |
Bed-days co-morbidity index (in 6 months prior to diagnosis) b | No statistically significant differences | |||
None | 1.00 | |||
1–4 days | 1.11 (0.94, 1.30) | 0.226 | ||
5–10 days | 1.20 (1.03, 1.39) | 0.017 | ||
⩾11 days | 1.33 (1.17, 1.50) | <0.001 | ||
Tumour subsite | ||||
Head of pancreas | 1.00 | 1.00 | ||
Body of pancreas | 1.01 (0.83, 1.24) | 0.918 | 1.19 (0.78, 1.83) | 0.425 |
Tail of pancreas | 0.97 (0.74, 1.28) | 0.849 | 1.18 (0.55, 2.54) | 0.665 |
Other | 1.12 (0.81, 1.55) | 0.499 | 0.86 (0.48, 1.52) | 0.595 |
Unspecified | 1.20 (1.10, 1.30) | <0.001 | 1.34 (1.15, 1.56) | <0.001 |
Tumour morphology | No statistically significant differences | |||
Neoplasm, not otherwise specified | 1.00 | |||
Carcinoma, not otherwise specified | 0.74 (0.51, 1.07) | 0.107 | ||
Adenocarcinoma, not otherwise specified | 0.62 (0.42, 0.93) | 0.022 | ||
Mucin-producing adenocarcinoma | 0.48 (0.27, 0.85) | 0.011 | ||
Other | 0.39 (0.23, 0.66) | <0.001 | ||
Microscopically verified | No statistically significant differences | |||
No | 1.00 | |||
Yes | 0.68 (0.55, 0.85) | 0.001 | ||
Metastases within 4 weeks of diagnosis b | ||||
No | 1.00 | 1.00 | ||
Yes | 1.92 (1.76, 2.10) | <0.001 | 1.93 (1.60, 2.33) | <0.001 |
Surgical resection b | Not applicable | |||
No | 1.00 | |||
Yes | 0.38 (0.31, 0.46) | <0.001 | ||
Other surgery b | Not applicable | |||
No | 1.00 | |||
Yes | 0.74 (0.67, 0.81) | <0.001 | ||
Biliary stent b | ||||
No | 1.00 | 1.00 | ||
Yes | 0.72 (0.65, 0.79) | <0.001 | 0.70 (0.57, 0.85) | <0.001 |
Chemotherapy b | No statistically significant differences | |||
No | 1.00 | |||
Yes | 0.59 (0.50, 0.71) | <0.001 | ||
Caseload of main treating consultant b | No statistically significant differences | |||
1 case | 1.00 | |||
2–4 cases | 0.87 (0.78, 0.97) | 0.013 | ||
5–9 cases | 0.90 (0.80, 1.02) | 0.088 | ||
⩾10 cases | 0.85 (0.77, 0.95) | 0.003 | ||
Specialty of main treating consultant b | No statistically significant differences | |||
Nonspecialist | 1.00 | |||
Specialist | 0.63 (0.50, 0.78) | <0.001 | ||
Clinician with an interest in the pancreas | 0.63 (0.48, 0.82) | 0.001 | ||
